Q2 2025 · 13F-HR
Sanofi (SNY, SNYNF)holdings as filed
Filed 2025-07-29 · accession 0000950123-25-006717
$175.7M
Reported value
10
Positions
2025-06-30
Period end
The Brief · Sanofi (SNY, SNYNF) · Q2 2025
AI · grounded in 13F
Sanofi SNY established a new position in MeiraGTx Holdings plc MGTX valued at $79.5M. The fund also initiated new stakes in Novavax NVAX for $43.3M and AnaptysBio ANAB for $18.2M. Additional new positions include Inhibrx Biosciences, Inc. INBX, Omada Health Inc. OMDA, and LAVA Therapeutics N.V. 4PKB.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G59665102 | MGTX | MeiraGTx Holdings plc | $79.5M | 45.3% | 12,197,737 | Common | SOLE |
| 670002401 | NVAX | Novavax | $43.3M | 24.7% | 6,880,481 | Common | SOLE |
| 032724106 | ANAB | AnaptysBio | $18.2M | 10.4% | 821,917 | Common | SOLE |
| 45720N103 | INBX | Inhibrx Biosciences, Inc. | $16.5M | 9.40% | 1,157,926 | Common | SOLE |
| 68170A108 | OMDA | Omada Health Inc. | $9.6M | 5.47% | 524,903 | Common | SOLE |
| N51517105 | 4PKB | LAVA Therapeutics N.V. | $2.5M | 1.44% | 1,919,455 | Common | SOLE |
| 28617K101 | ELDN | Eledon | $2.2M | 1.26% | 814,980 | Common | SOLE |
| 45790W108 | — | Inozyme, Inc | $1.8M | 1.01% | 443,255 | Common | SOLE |
| 449585108 | 1K0 | IGM Biosciences | $1.6M | 0.92% | 1,438,975 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio Inc. | $363,684 | 0.21% | 244,083 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.